Analiza promotorskih varijanti gena CYP2C19 i njihova uloga u predviđanju terapijskog odgovora na lek klopidogrel kod pacijenata sa infarktom miokarda i stenozom karotida

Novković, Mirjana M.

Doktorand:

Novković, Mirjana M.

Fakultet:

Biološki fakultet

Napomena:

Rok za dostavljanje primedbi na doktorsku disertaciju je istekao.

Datum postavljanja na uvid javnosti:

30-08-2018

Datum odbrane:

20-11-2018

Objavljeni radovi:

[1]

Novkovic M, Matic D, Kusic-Tisma J, Antonijevic N, Radojkovic D, Rakicevic L (2018). Analysis of CYP2C19 genotype associated with bleeding in Serbian STEMI-patients undergone primary PCI and treated with clopidogrel.Eur J Clin Pharmacol.Apr;74(4):443-451. DOI 10.1007/s00228-017-2401-5 https://www.ncbi.nlm.nih.gov/pubmed/29260275 IF2016 2.679; M22

[2]

MitropoulouC, FragoulakisV, RakicevicL, NovkovicM, VozikisA, MaticD, AntonijevicN, RadojkovicD, vanSchaikRH, PatrinosG (2016).Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics DOI 10.2217/pgs-2016-0052. https://www.ncbi.nlm.nih.gov/pubmed/?term=10.2217%2Fpgs-2016-0052 IF2014 3,218; M21